報價延遲最少15分鐘:2025/01/12 03:49 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.54 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-15.00/-0.65
|
|
企業價值
11.67M
|
| 資產負債 |
|
每股賬面淨值
18.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:49 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. |